2-二乙氨基乙硫醇 | 100-38-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-二乙氨基乙硫醇
• 中文别名: Β-二乙氨基乙硫醇；2-二乙基氨基乙基硫醇；二乙氨基乙硫醇
• 英文名称: 2-(diethylamine)ethanethiol
• 英文别名: 2-(diethylamino)ethanethiol；diethylaminoethanethiol；N,N-diethylcysteamine；DEC
• CAS: 100-38-9
• 化学式: C₆H₁₅NS
• mdl: MFCD00066258
• 分子量: 133.258
• InChiKey: YBDSNEVSFQMCTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  4.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-二乙氨基乙硫醇 在 sodium hypoiodite 作用下， 生成 2,2'''-二硫基双三乙胺
  参考文献：
  名称：

  Action of bases on 1-mercaptopropyltrimethyl-ammonium iodide

  摘要：

  DOI：

  10.1021/jo01285a012
• 作为产物：
  描述：

  N,N-二乙基氯乙胺 在 乙醇 、 alkali hydrogensulfide 作用下， 生成 2-二乙氨基乙硫醇
  参考文献：
  名称：

  M EASUREMENT OF P EDIATRIC I LLNESS S EVERITY U SING S IMPLE P RETRANSPORT V ARIABLES

  摘要：

  Objective: To test the hypothesis that pretransport variables can predict in-hospital mortality that will correlate with major interventions and unplanned events during interfacility transport. Methods: A cohort of children (n = 2,253) transported by a specialized pediatric team to a children's hospital were studied. At the time of referral, data collected included age (months), heart rate, systolic blood pressure, respiratory rate, retractions, stridor or wheezing, seizures, skin perfusion, oxygen requirement, and mental status. Using univariate and stepwise logistic regression, variables predictive of in-hospital mortality were selected from a training set (n = 1,111) and assigned integers based on their computed coefficients. Probability of in-hospital mortality was calculated using the total integer score and age. The risk of mortality derived from the training set was validated in the remaining patients (n = 1,142) by comparing the observed and predicted mortalities. Major interventions performed and unplanned events were determined for each of five predetermined mortality risk groups. Results: Variables (integers) predicting in-hospital mortality included systolic blood pressure (11), respiratory rate (6), oxygen requirement (11), and altered mental status (11). Observed mortality was similar to predicted mortality in all risk categories for the validation sample. As risk of mortality increased, so did the performance of major interventions and the occurrence of unplanned events. Conclusion: Four pretransport variables predicted in-hospital mortality. Risk of mortality correlated with the incidence of major patient interventions, and the occurrence of unplanned events increased as well. This model might be useful in comparing different transport systems using severity-adjusted assessment of children requiring interfacility transport.

  DOI：

  10.1080/10903120190939986
• 作为试剂：
  描述：

  (1R,2R)-methyl-2-(2-fluoro-6-methoxy-4-pentylphenyl)-4-oxocyclohexanecarboxylate 在 盐酸 、 sodium hydride 、 溶剂黄146 、 2-二乙氨基乙硫醇 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 乙醚 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 13.25h， 生成 四氢大麻酚
  参考文献：
  名称：

  的对映选择性全合成（ - ） - Δ 8 -THC和（ - ） - Δ 9 -THC通过不对称催化氢化反应和S Ñ的Ar环化

  摘要：

  （ - ） - Δ的高效不对称全合成8四氢大麻酚（（ - ） - Δ 8 -THC）（13个步骤，35％）和（ - ） - Δ 9 -四氢大麻酚（（ - ） - Δ 9 -THC ）（14步，30％）通过动态动力学拆分和分子内S N Ar环化反应，通过钌催化外消旋α-芳基环酮的不对称氢化反应而开发。

  DOI：

  10.1021/ol303351y

文献信息

• [EN] AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'AZÉTIDIN-3-YLMÉTHANOL EN TANT QUE MODULATEURS DU RÉCEPTEUR CCR6
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2021219849A1

  公开（公告）日：2021-11-04

  The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.

  本发明涉及式(I)化合物，其合成以及作为CCR6受体调节剂用于治疗或预防各种疾病、状况或障碍。
• [EN] TRIAZINES SUITABLE FOR USE IN FABRIC TREATMENT COMPOSITIONS<br/>[FR] TRIAZINES POUVANT ETRE UTILISEES DANS DES COMPOSITIONS DE TRAITEMENT DE TISSUS
  申请人：UNILEVER PLC

  公开号：WO2005123699A1

  公开（公告）日：2005-12-29

  A water-soluble, triazine-based, non-dye, cellulose cross-linking agent that has a highly flexible linking group between at least two, mono-reactive cross-linking moieties and further hydrophilic or non-hydrophilic substituents, being preferrably represented by the general formula (I): (R1)(X1)T-L1-B-T(X2)(R2) wherein: R1 et R2 are cellulose-unreactive substituent groups on the s-triazine (T) and may be the same or different, X1 and X2 are leaving groups on the s-triazine which are lost on reaction with cellulose and may be the same or different, L1 et L2 are linking groups, an may be the same or different or absent, B is the bridging group comprising or consisting of at least one aliphatic polyoalkylene chain.

  一种水溶性、基于三嗪的、非染料、纤维素交联剂，其在至少两个单反应性交联基团之间具有高度灵活的连接基团，并且进一步具有亲水性或非亲水性取代基，优选由通式（I）表示：（R1）（X1）T-L1-B-T（X2）（R2）其中：R1和R2是三嗪（T）上的纤维素不反应取代基团，可以相同也可以不同，X1和X2是三嗪上的脱离基团，在与纤维素反应时失去，并且可以相同也可以不同，L1和L2是连接基团，可以相同也可以不同或不存在，B是包含或由至少一个脂肪族聚烯烃链组成的桥接基团。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：INFLAZOME LTD

  公开号：WO2019211463A1

  公开（公告）日：2019-11-07

  The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

  本发明涉及取代的含氮杂环化合物，例如磺酰基三唑，其中杂环环进一步取代，可选地通过类似-NH-的连接基团，与环状基团相连，该环状基团在α-位置进一步取代。本发明还涉及相关的盐、溶剂合物、前药和药物组合物，以及这些化合物在治疗和预防医学疾病和疾病中的使用，尤其是通过NLRP3抑制。
• AMINE-BORANES BEARING BORANE-INTOLERANT FUNCTIONALITIES
  申请人：Purdue Research Foundation

  公开号：US20180051040A1

  公开（公告）日：2018-02-22

  Disclosed herein is the preparation of functional group containing amine-boranes from the corresponding amines. The mild reaction conditions allow for the direct preparation of several hitherto inaccessible amine-boranes containing a functional moiety, such as but not limited to, alkene, alkyne, hydroxyl, thiol, acetal, ester, amide, nitrile, nitro, and alkoxysilane.

  本文披露了从相应胺制备含有胺硼烷的官能团的方法。温和的反应条件使得可以直接制备几种迄今为止无法获得的含有官能团的胺硼烷，例如但不限于烯烃、炔烃、羟基、硫醇、缩醛、酯、酰胺、腈、硝基和烷氧基硅烷。
• 2-ethyl N,N-bis(2-chloroethyl)phosphorodiamidates
  申请人：Laborde Edgardo

  公开号：US20090156559A1

  公开（公告）日：2009-06-18

  2-[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates and their salts, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer and autoimmune diseases, alone and in combination with other therapies.

  2-[2-(取代氨基)乙基]磺酰基}乙基N,N-双(2-氯乙基)磷酰二胺酸酯及其盐，其制备方法和制备中间体，含有它们的药物组合物，以及使用它们的治疗方法。这些化合物可用于治疗癌症和自身免疫性疾病，单独或与其他疗法结合使用。

表征谱图